Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A reproducible model of intramedullary spinal cord tumor in rats bearing RG2 cells.

Zhuang Y, Zhao W, Zhang W, Wei H, Huang X, Cai G, Fu C, Wang C, Wang R, Shi S, Yang W, Chen C.

Oncotarget. 2017 May 9;8(19):30971-30977. doi: 10.18632/oncotarget.16045.

2.

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Saha D, Ahmed SS, Rabkin SD.

Drugs Future. 2015;40(11):739-749.

3.

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.

Takahashi M, Valdes G, Hiraoka K, Inagaki A, Kamijima S, Micewicz E, Gruber HE, Robbins JM, Jolly DJ, McBride WH, Iwamoto KS, Kasahara N.

Cancer Gene Ther. 2014 Oct;21(10):405-410. doi: 10.1038/cgt.2014.38. Epub 2014 Oct 10.

4.

Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity.

Lin AH, Burrascano C, Pettersson PL, Ibañez CE, Gruber HE, Jolly DJ.

J Virol. 2014 Sep 1;88(17):10066-77. doi: 10.1128/JVI.02300-13. Epub 2014 Jun 25.

5.

MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.

Lin AH, Timberlake N, Logg CR, Liu Y, Kamijima S, Diago O, Wong K, Gammon DK, Ostertag D, Hacke K, Yang EC, Gruber H, Kasahara N, Jolly DJ.

Hum Gene Ther. 2014 Aug;25(8):759-71. doi: 10.1089/hum.2012.216. Epub 2014 Jun 18.

6.

Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.

Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N, Mueller BM, Kruse CA.

Clin Cancer Res. 2013 Aug 1;19(15):4137-48. doi: 10.1158/1078-0432.CCR-12-3735. Epub 2013 Jun 18.

7.

Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.

Yin D, Zhai Y, Gruber HE, Ibanez CE, Robbins JM, Kells AP, Kasahara N, Forsayeth J, Jolly DJ, Bankiewicz KS.

Cancer Gene Ther. 2013 Jun;20(6):336-41. doi: 10.1038/cgt.2013.25. Epub 2013 May 24.

8.

Current status of gene therapy for brain tumors.

Murphy AM, Rabkin SD.

Transl Res. 2013 Apr;161(4):339-54. doi: 10.1016/j.trsl.2012.11.003. Epub 2012 Dec 11.

9.

Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A, Jolson D, Amundson K, Buckley T, Lohse D, Lin A, Burrascano C, Ibanez C, Kasahara N, Gruber HE, Jolly DJ.

Mol Ther. 2012 Sep;20(9):1689-98. doi: 10.1038/mt.2012.83. Epub 2012 May 1. Erratum in: Mol Ther. 2013 Feb;21(2):494.

10.

Cellular and vaccine therapeutic approaches for gliomas.

Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA.

J Transl Med. 2010 Oct 14;8:100. doi: 10.1186/1479-5876-8-100. Review.

11.

Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.

Kubo S, Haga K, Tamamoto A, Palmer DJ, Ng P, Okamura H, Kasahara N.

Mol Ther. 2011 Jan;19(1):76-82. doi: 10.1038/mt.2010.182. Epub 2010 Aug 31.

12.

Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.

Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF, Hong JS, Sorscher EJ, Chen TC, Kasahara N.

Cancer Gene Ther. 2010 Sep;17(9):614-23. doi: 10.1038/cgt.2010.17. Epub 2010 May 14.

13.

Gene- and viral-based therapies for brain tumors.

Asadi-Moghaddam K, Chiocca EA.

Neurotherapeutics. 2009 Jul;6(3):547-57. doi: 10.1016/j.nurt.2009.04.007.

14.

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Barth RF, Kaur B.

J Neurooncol. 2009 Sep;94(3):299-312. doi: 10.1007/s11060-009-9875-7. Epub 2009 Apr 21. Review.

15.

Supplemental Content

Support Center